Active, not recruitingPhase 1NCT07019883
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Studying Avian influenza
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- H5 AC-Anhui RNA Vaccine(biological)
- Enrollment
- 80 enrolled
- Eligibility
- 18-49 years · All sexes
- Timeline
- 2025 – 2026
Study locations (3)
- Duke Vaccine and Trials Unit, Durham, North Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Baylor College of Medicine, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07019883 on ClinicalTrials.govOther trials for Avian influenza
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc.
- RECRUITINGPHASE3NCT07240558Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)University Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE4NCT07275060Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartCanadian Immunization Research Network
- RECRUITINGPHASE1, PHASE2NCT06842173Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsButantan Institute
- RECRUITINGNANCT06850298H5N1 Milk Detection StudyEmory University